These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17186199)

  • 1. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
    Brüggenjürgen B; Lindgren P; Ehlken B; Rupprecht HJ; Willich SN
    Eur J Health Econ; 2007 Mar; 8(1):51-7. PubMed ID: 17186199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
    Cui M; Tu CC; Chen EZ; Wang XL; Tan SC; Chen C
    Adv Ther; 2016 Sep; 33(9):1600-11. PubMed ID: 27397588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
    J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
    Lindgren P; Jönsson B; Yusuf S
    J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
    Theidel U; Asseburg C; Giannitsis E; Katus H
    Clin Res Cardiol; 2013 Jun; 102(6):447-58. PubMed ID: 23474908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
    Davies A; Bakhai A; Schmitt C; Barrett A; Graham-Clarke P; Sculpher M
    J Med Econ; 2013; 16(4):510-21. PubMed ID: 23339464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
    Main C; Palmer S; Griffin S; Jones L; Orton V; Sculpher M; Henderson R; Sudlow C; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
    Berger K; Hessel F; Kreuzer J; Smala A; Diener HC
    Curr Med Res Opin; 2008 Jan; 24(1):267-74. PubMed ID: 18053318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
    Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
    Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
    Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
    Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
    Karnon J; Brennan A; Pandor A; Fowkes G; Lee A; Gray D; Coshall C; Nicholls C; Akehurst R
    Curr Med Res Opin; 2005 Jan; 21(1):101-12. PubMed ID: 15881481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
    Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
    Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
    Latour-Pérez J; de Miguel Balsa E; Betegón L; Badia X
    Value Health; 2008; 11(5):853-61. PubMed ID: 18489507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.